What is going on with EIGR?
Eiger Biopharmaceuticals (EIGR) stock is higher today after the company announced that its lead clinical drug, Peginterferon Lambda (Lambda), will be added to the ongoing, multi-center, Phase 3 TOGETHER platform study.
TOGETHER is an ongoing, multi-center, randomized, placebo-controlled Phase 3 study evaluating multiple therapeutics in newly diagnosed, non-hospitalized patients with COVID-19. Shares of EIGR increased 0.35% to $8.52 as of Monday at 1:57pm.
What does this mean for Eiger BioPharmaceuticals?
The addition of Lamba into the TOGETHER study is an excellent opportunity for the company to prove Lambda's efficacy against COVID-19, and its promise as a potential outpatient therapy. Lambda could prove to be particularly effective against different strains, as Lambda stimulates immune responses that are critical for the development of host protection during viral infections, which are helpful in fighting Covid variants.
"The COVID-19 pandemic continues to be a global public health emergency, and outpatient treatments that can be quickly and efficiently administered to newly diagnosed SARS-CoV-2 patients are desperately needed with a goal of reducing COVID-19 complications," said Edward Mills, PhD, who is leading the study.
The primary endpoint is a clinical outcome comparing emergency room visits and/or hospitalization in each active arm versus placebo. Each target arm will enroll up to 800 patients.
EIGR has an Overall Score of 42. Find out what this means to you and get the rest of the rankings on EIGR!
Eiger BioPharmaceuticals Inc is a late-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
